Stem Cells: Current Status and Therapeutic Implications

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2020 Nov 25

PMID 33233552

Citations 4

Authors

Kaladhar B Reddy

Affiliations

Soon will be listed here.

Abstract

Cancer stem cells (CSCs) are a class of pluripotent cells that have been observed in most types of cancers. Evolving evidence suggests that CSCs, has the ability to self-renew and initiate tumors, may be responsible for promoting therapeutic resistance, tumor recurrence and metastasis. Tumor heterogeneity is originating from CSCs and its progenitors are recognized as major difficulty in efficaciously treating cancer patients. Therefore, understanding the biological mechanisms by which CSCs survive chemo- and-radiation therapy has the potential to identify new therapeutic strategies in the future. In this review, we summarized recent advances in CSC biology and their environment, and discuss about the potential therapies to prevent therapeutic resistance.

Citing Articles

Is cancer an intelligent species?.

Nicolazzo C, Francescangeli F, Magri V, Giuliani A, Zeuner A, Gazzaniga P Cancer Metastasis Rev. 2023; 42(4):1201-1218.

PMID: 37540301 PMC: 10713722. DOI: 10.1007/s10555-023-10123-0.

Single-Cell Sequencing Reveals that DBI is the Key Gene and Potential Therapeutic Target in Quiescent Bladder Cancer Stem Cells.

Yao J, Liu Y, Yang J, Li M, Li S, Zhang B Front Genet. 2022; 13:904536.

PMID: 35769986 PMC: 9235029. DOI: 10.3389/fgene.2022.904536.

Generation of Cancer Stem/Initiating Cells by Cell-Cell Fusion.

Dittmar T Int J Mol Sci. 2022; 23(9).

PMID: 35562905 PMC: 9101717. DOI: 10.3390/ijms23094514.

RNA-based therapies: A cog in the wheel of lung cancer defense.

Khan P, Siddiqui J, Lakshmanan I, Ganti A, Salgia R, Jain M Mol Cancer. 2021; 20(1):54.

PMID: 33740988 PMC: 7977189. DOI: 10.1186/s12943-021-01338-2.

References

Hoey T, Yen W, Axelrod F, Basi J, Donigian L, Dylla S . DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell. 2009; 5(2):168-77. DOI: 10.1016/j.stem.2009.05.019. View

Xu L, Yin S, Banerjee S, Sarkar F, Reddy K . Enhanced anticancer effect of the combination of cisplatin and TRAIL in triple-negative breast tumor cells. Mol Cancer Ther. 2011; 10(3):550-7. PMC: 3053434. DOI: 10.1158/1535-7163.MCT-10-0571. View

Shultz L, Lyons B, Burzenski L, Gott B, Chen X, Chaleff S . Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005; 174(10):6477-89. DOI: 10.4049/jimmunol.174.10.6477. View

Roesch A, Fukunaga-Kalabis M, Schmidt E, Zabierowski S, Brafford P, Vultur A . A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010; 141(4):583-94. PMC: 2882693. DOI: 10.1016/j.cell.2010.04.020. View

Rodgerson D, Harris A . A comparison of stem cells for therapeutic use. Stem Cell Rev Rep. 2011; 7(4):782-96. DOI: 10.1007/s12015-011-9241-y. View

Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K . Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004; 118(2):149-61. DOI: 10.1016/j.cell.2004.07.004. View

Cheng W, Liu T, Wan X, Gao Y, Wang H . MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 2012; 279(11):2047-59. DOI: 10.1111/j.1742-4658.2012.08589.x. View

Misra S, Toole B, Ghatak S . Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem. 2006; 281(46):34936-41. DOI: 10.1074/jbc.C600138200. View

Meligy F, Shigemura K, Behnsawy H, Fujisawa M, Kawabata M, Shirakawa T . The efficiency of in vitro isolation and myogenic differentiation of MSCs derived from adipose connective tissue, bone marrow, and skeletal muscle tissue. In Vitro Cell Dev Biol Anim. 2012; 48(4):203-15. DOI: 10.1007/s11626-012-9488-x. View

10.

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

11.

Plaks V, Koopman C, Werb Z . Cancer. Circulating tumor cells. Science. 2013; 341(6151):1186-8. PMC: 3842225. DOI: 10.1126/science.1235226. View

12.

Zhou J, Zhu X, Wu S, Guo J, Zhang K, Xu C . Epithelial-mesenchymal transition status of circulating tumor cells in breast cancer and its clinical relevance. Cancer Biol Med. 2020; 17(1):169-180. PMC: 7142848. DOI: 10.20892/j.issn.2095-3941.2019.0118. View

13.

Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L . Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology. 2010; 140(1):297-309. DOI: 10.1053/j.gastro.2010.10.005. View

14.

Ocana O, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S . Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell. 2012; 22(6):709-24. DOI: 10.1016/j.ccr.2012.10.012. View

15.

Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H . The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011; 17(2):211-5. PMC: 3076220. DOI: 10.1038/nm.2284. View

16.

Vidal S, Rodriguez-Bravo V, Galsky M, Cordon-Cardo C, Domingo-Domenech J . Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene. 2013; 33(36):4451-63. DOI: 10.1038/onc.2013.411. View

17.

Robinson N, Taylor D, Schiemann W . Stem cells, immortality, and the evolution of metastatic properties in breast cancer: telomere maintenance mechanisms and metastatic evolution. J Cancer Metastasis Treat. 2019; 5. PMC: 6706062. DOI: 10.20517/2394-4722.2019.15. View

18.

Dalerba P, Dylla S, Park I, Liu R, Wang X, Cho R . Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007; 104(24):10158-63. PMC: 1891215. DOI: 10.1073/pnas.0703478104. View

19.

Codd A, Kanaseki T, Torigo T, Tabi Z . Cancer stem cells as targets for immunotherapy. Immunology. 2017; 153(3):304-314. PMC: 5795182. DOI: 10.1111/imm.12866. View

20.

Chae Y, Kim J . Cancer stem cell metabolism: target for cancer therapy. BMB Rep. 2018; 51(7):319-326. PMC: 6089865. DOI: 10.5483/bmbrep.2018.51.7.112. View